Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Ropidoxuridine (IPdR) and IMRT in Gastrointestinal Cancers
NCT02381561Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropidoxuridine in gastrointestinal cancer, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose up to 28 days. Started Feb 2016; status: active, not recruiting.
02
Drugs
ropidoxuridine
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT02381561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381561.